Objectives: To evaluate the different insulin regimens and types of insulin used in our population of type 1 diabetes (DM1) patients in the last revision in our clinic.
Method: A descriptive study was carried out in our population of 535 DM1 patients. They had their initial diagnosis between 1967 and 2014.
Results: In our population, 47.3% were women and 52.3% were men. The mean age of our patients was 33.8 years (S.D. ±12.31 years) and the mean age of diagnosis was 16.67 (S.D. 11± years). 17.39% of our population was taking antiplatelet therapy. 17.4% had hypertension, and 36% cdyslipidemia. There were 22.9% smokers and 10.3%. who had given up. The glycated hemoglobin value was 7.8 (S.D. ±1.28%) and the body mass index 27.18 (S.D. 4± kg/m2). 91% had previously received diabetic education assistance, and 32.1% completed the program. Total insulin dose was 40.52 units (S.D. ±29.9 IU) with 0.68 (S.D. ±0.33 U/kg). Insulin regimes used were: basal-bolus 91.3%, basal alone 1.5%, prandial plus mix 2.7% and mix combination 4.5%. In those using basal-bolus regimen, 42.67 (S.D. ±25.8%) of total insulin dose (TID) was prandial insulin and basal insulin 54.05 (S.D. ±17.2%):
- Prandial insulins used were: lispro 41%, aspart 46.5%, glulisin 7.7% and regular 4.9%.
- Basal insulin used were: glargine 85.4%, detemir 13.5%, lispro protamine 0.2%, NPH 0.8%.Time of injection was breakfast in 17.9%, lunch 15.8%, dinner 17.6%, before bedtime 34.2%; 14.5% in split doses. In 86%, the split dose regimen was given breakfast and dinner and 14% breakfast and before bedtime. We observed a higher dose of insulin among patients with two daily doses of basal insulin: 35.9 (S.D. ±20) vs 25.54 (S.D. ±12.2) IU (P <0.05).
Conclusions: Basal-bolus therapy is the most used regimen in our DM1 population. Those patients using two basal doses per day needed higher TID. The majority of our patients had educational support but less than a half complete the educational program. It is important to aware our patients to finish these activities to better self control of their disease.
20 - 23 May 2017
European Society of Endocrinology